PatientsVille.com Logo

Diabetic retinopathy and Vegf

PatientsVille

Diabetic Retinopathy Symptoms and Causes

If you have diabetes, your blood glucose, or blood sugar, levels are too high. Over time, this can damage your eyes. The most common problem is diabetic retinopathy. It is a leading cause of blindness in American adults.

Your retina is the light-sensitive tissue at the back of your eye. You need a healthy retina to see clearly. Diabetic retinopathy damages the tiny blood vessels inside your retina.

You may not notice it at first. Symptoms can include

  • Blurry or double vision
  • Rings, flashing lights, or blank spots
  • Dark or floating spots
  • Pain or pressure in one or both of your eyes
  • Trouble seeing things out of the corners of your eyes

Treatment often includes laser treatment or surgery, with follow-up care.

Two other eye problems can happen to people with diabetes. A cataract is a cloud over the lens of your eye. Surgery helps you see clearly again. Glaucoma happens when pressure builds up in the eye, damaging the main nerve. Eye drops or surgery can help.

If you have diabetes, you should have a complete eye exam every year. Finding and treating problems early may save your vision.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for diabetic retinopathy

diabetic retinopathy treatment research studies

Vegf clinical trials, surveys and public health registries


Find Drug Side Effect reports



Vegf Side Effects

Renal Failure Acute (3)
Vitreous Haemorrhage (3)
Loss Of Consciousness (3)
Cerebrovascular Accident (3)
Dizziness (3)
Coronary Artery Stenosis (3)
Blood Creatinine Increased (2)
Haemodialysis (2)
Cardiac Failure Congestive (2)
Abdominal Pain (2)
Diabetic Ketoacidosis (2)
Hypotension (2)
Eructation (2)
Diabetic Hyperosmolar Coma (2)
Angle Closure Glaucoma (2)
Renal Failure (2)
Myocardial Infarction (2)
Metabolic Acidosis (2)
Retinal Haemorrhage (2)
Renal Impairment (2)
Vitreous Detachment (2)
Vertigo (2)
Visual Acuity Reduced (2)
Retinal Aneurysm (1)
Subdural Haematoma (1)
Retinal Exudates (1)
Upper Gastrointestinal Haemorrhage (1)
Red Blood Cell Sedimentation Rate Increased (1)
Transferrin Saturation Decreased (1)
Optic Nerve Disorder (1)
Vomiting (1)
Oedema Peripheral (1)
Palpitations (1)
Peripheral Arterial Occlusive Disease (1)
Pilonidal Cyst (1)
Pneumonia Aspiration (1)
Mental Status Changes (1)
Macular Hole (1)
Ischaemic Stroke (1)
Malaise (1)
Mastoiditis (1)
Muscular Weakness (1)
Hyphaema (1)
Hyperkalaemia (1)
Haematemesis (1)
Myocardial Ischaemia (1)
Headache (1)
Hemianopia Homonymous (1)
Hiatus Hernia (1)
Nasopharyngitis (1)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Hello, I was given Azastin or Avastin for macular edema. I also have retinopathy from diabetes. I was given this shot in my eye in April of this yr. Within 2 days, I had cellulitis in both legs. Horrible pain. Dark red all over from my knees to my

I'm over 80, very active working 6 days a week, walking briskly about 6 x 10 minutes daily, with Verapamil and 100 mg aspirin (also diabetic and asthmatic - completely under control). Had a biological aortic valve replacement, very s

My father is 68 and retired, he is also diabetic. He suffers from severe joints, hip and back pain. He has been using panadol extra strength but finds it takes too long to act. He is also allergic to aspirin and was hospitalized with a ruptured u

Hello, I was given Azastin or Avastin for macular edema. I also have retinopathy from diabetes. I was given this shot in my eye in April of this yr. Within 2 days, I had cellulitis in both legs. Horrible pain. Dark red all over from my knees to my

<b>Describe I was put on Deplin 15mg to supplement the antidepressent that I have been on for for 3wks now. This was just 2 days ago. I feel a little better, but I am an insulin dependent diabetic, and my sugars have actually gone up to

my preterm baby was undergoing laser treatment for (ROP) retinopathy of prematurity,when she experienced apnoea n then bradycardia,today my child is 2yrs 7 mths n has detected to have cerebral palsy can the

48YO male, obese, diabetic, hypertensive, mild anxiety and depression. R BKA, R Acetabula fracture 13 years ago from motorcycle accident. Swollen gall bladder removed during hospitalization. Current meds include Metformin (withheld pre- and post- ct)

ACTUALLY I AM DIABETIC TOO BUT I NEED TO REDUCE WEIGHT DOES GALVUS HELPS YOU TO REDUCE WEIGHT? OR TO GAIN WEIGHT?

After just 7 days of starting pioglitazone(15 mg.daily) ,I developed loss of taste for mainly sugar and salt,but unfortunatyely i couldnot guess pioglitazone as possible cause. I am type 2 diabetic and hypertensive and taking metformin,glimeperide,li

After taking 500mg of fortamet for two weeks i am having blured vision . i am type 2 diabetic.

Central Serous Retinopathy - leaking of vessels behind the reitna (did you know that Levothyrozine is a steroid?)

Diabetic Retinopathy Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Anterior and Posterior Segment Vascular Changes Following Laser and Anti-Vascular Endothelial Growth Factor (Vegf) Treatment of Diabetic Retinopathy
Condition: Diabetic Macular Edema
Intervention:
Outcome Measures: Quantitative inner retinal blood flow;   Mean retinal thickness for an annulus centered on fovea;   Best Corrected Visual Acuity (LogMAR, EDTRS);   Quantitative anterior blood flow;   Mean angle opening distance and trabecular-iris spur area
2 Recruiting Prospective Randomized Trial of Proton Beam Combined With Anti-Vegf Therapy for Exudative Age-related Macular Degeneration (AMD)
Condition: Exudative Age-related Macular Degeneration
Interventions: Drug: 24GyE proton and Anti-Vegf;   Drug: 16GyE and anti-Vegf;   Drug: Sham Irradiation and anti-Vegf
Outcome Measures: Number of eyes with 3 or more lines of vision loss from baseline;   number of anti-Vegf therapy;   number of eyes with 3 or more lines of visual acuity gain from baseline;   Number of eyes with radiation retinopathy or papillopathy
3 Unknown  Does Vascular Endothelial Growth Factor (Vegf) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With Vegf Inhibitors in Patients With Choroidal NeoVascularization (CNV)?
Conditions: Choroidal Neovascularization;   Age-Related Macular Degeneration
Intervention: Genetic: Vegf genotyping
Outcome Measures: Visual acuity using ETDRS charts;   Central retinal thickness (Optical coherence tomography);   Vegf genotyping
4 Not yet recruiting UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-Vegf Effects in Patients With neovascuLar AMD
Condition: Neovacular Age-related Macular Degeneration
Intervention: Procedure: Vegf level assessment
Outcome Measures: Percent reduction in blood Vegf at month 3 following intravitreal (IVT) injection of anti-Vegf agent;   Percent reduction in blood Vegf level overtime;   Correlation between blood detected Vegf level and measured concentration of anti-Vegf agent overtime;   Mean change from baseline in Best Corrected Visual Acuity (BCVA) of the study eye over time;   mean change in central retinal thickness (CRT) of the study eye over time;   Number of ocular and systemic Adverse Events
5 Recruiting EG-Vegf : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction
Conditions: Pre-eclampsia;   Intra-uterine Growth Retardation
Intervention: Other: blood sample and doppler Ultrasound of uterine arteries
Outcome Measures: Measure of the circulating levels of EG-Vegf in the sera of pregnant woman between 14 and 18 WG;   Correlation between the level of uterine artery transformation and the level of EG-Vegf.;   Measure the circulating levels of other pro and/or anti-angiogenic factors;   Measure the circulating levels of the new angiogenic factor EG-Vegf;   Measure the circulating levels of the new angiogenic factor EG-Vegf in the sera
6 Recruiting Efficacy and Safety of Vegf Trap Eye in Diabetic Macular Edema (DME) With Central Involvement
Condition: Macular Edema
Interventions: Biological: Aflibercept (Eylea, Vegf Trap-Eye, BAY86-5321);   Procedure: Laser photocoagulation
Outcome Measures: Change in best-corrected visual acuity (BCVA) in ETDRS (Early Treatment Diabetic Retinopathy Study) letter score;   Change in retinal thickness;   Proportion of subjects who gain a threshold change in visual acuity;   Change in National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) near activities subscale;   Change in National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) distance activities subscale
7 Unknown  The Effect of a Single Intravitreal Anti-Vegf Therapy on Optic Nerve Head Perfusion
Conditions: Macular Degeneration;   Regional Blood Flow;   Vascular Endothelial Growth Factor
Intervention: Drug: ranibizumab, bevacizumab or pegaptanib
Outcome Measures: Optic nerve head blood flow;   Choroidal blood flow;   Retrobulbar blood flow;   Intraocular pressure;   Systemic blood pressure
8 Unknown  Expression of Vegf-C and Vegf-CR in Oral Cancers and Premalignant Lesions
Condition: Oral Cancer
Intervention:
Outcome Measure:
9 Recruiting A Retrospective Study of Anti-Vascular Endothelial Growth Factor (Vegf) Injections for Retinal Vein Occlusion or Diabetic Macular Edema
Conditions: Retinal Vein Occlusion;   Macular Edema
Intervention: Drug: Anti-Vegf
Outcome Measures: Percentage of Patients with Best Corrected Visual Acuity (BCVA) of 20/40 or Better and Central Retinal Thickness (CRT) ≤250 µm on Time Domain (TD) Optical Coherence Tomography (OCT) or ≤300 µm on Spectral Domain (SD) OCT in the Study Eye;   Percentage of Patients with BCVA of 20/40 or Better in the Study Eye;   Percentage of Patients with CTR of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye;   Percentage of Patients with Both BCVA 20/40 or Better or CTR ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye;   Percentage of Patients with BCVA 20/40 or Worse or CRT ≥250 µm on TD OCT or ≥300 µm on SD OCT AND, Compared with the Visit 3 Months Before the Current Visit, Patient had a Gain of <1 Line in BCVA or a Decrease of <50 µm in CRT in the Study Eye;   Mean BCVA in the Study Eye;   Change from Baseline in BCVA in the Study Eye;   Percentage of Patients with an Increase from Baseline of ≥2 Lines in BCVA in the Study Eye;   Percentage of Patients with an Increase from Baseline of ≥3 Lines in BCVA in the Study Eye;   Change from Baseline in CRT in the Study Eye;   Time to Improvement of ≥2 Lines in BCVA in the Study Eye;   Time to Improvement of ≥3 Lines in BCVA in the Study Eye;   Time to Improvement in BCVA to 20/40 or Better in the Study Eye;   Time to Improvement in CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye;   Time to Improvement to Both 20/40 or Better in BCVA and Improvement in CRT of ≤250 µm on TD OCT or ≤300 µm on SD OCT in the Study Eye;   Time Between Anti-Vegf Injections in the Study Eye;   Number of Anti-Vegf Injections in the Study Eye;   Change in BCVA Following the Last Anti-Vegf Injection in the Study Eye;   Percentage of Patients switching to a 2nd or 3rd Anti-Vegf After the First Injection in the Study Eye;   Percentage of Patients Switching Among Different Anti-Vegfs in the Study Eye;   Percentage of Patients with Focal Laser in the Study Eye;   Percentage of Patients with Panretinal Photocoagulation (PRP) in the Study Eye;   Percentage of Patients Using Corticosteroids in the Study Eye;   Percentage of Patients with a Loss, Gain and No Change from Baseline in BCVA by ≥1 Line in the Study Eye;   Percentage of Patients with Glaucoma Laser Surgery in the Study Eye;   Percentage of Patients with Incisional Glaucoma Surgery in the Study Eye;   Percentage of Phakic Patients with Cataract Surgery in the Study Eye
10 Recruiting EndocardialVascularEndothelialGrowth Factor D(Vegf-D)Gene Therapy for the Treatment of Severe Coronary Heart Disease
Conditions: Angina Pectoris;   Myocardial Infarction
Intervention: Biological: Vegf-D gene transfer
Outcome Measures: Assessments for safety and tolerability as measured as the acute and late adverse effects, laboratory parameters, biodistribution of the vector, anti-adenovirus antibodies and Vegf-levels before and in several time points after the gene transfer.;   Efficacy of GT to increase myocardial perfusion in MRI and PET.;   Functional capacity in exercise test, LV-function in echocardiography, arrhythmias in 24-hours Holter-recording will be analyzed.;   Improvement in symptoms, QOL and medication.
11 Recruiting Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-Vegf Therapy
Conditions: Ophthalmology;   Macular Edema;   Macular Degeneration
Intervention: Drug: Ranibizumab (or other DME treatment)
Outcome Measures: Changes in visual acuity, assessed by Early Treatment Diabetic Retinopathy Study (ETDRS) or SNELLEN;   Demographic and clinical characteristics (Age, sex, race, employment status, severity of DME);   Mean time from diagnosis to first commencement with an approved anti-Vegf therapy;   Changes in retinal thickness, measured by Optical Coherence Tomography (OCT);   Presence of clinically significant macular edema, measured as defined by the ETDRS Research Group;   Resource utilization in terms of treatment choices, frequency and duration;   Mean change in quality of life score (using the NEI VFQ 25), only in countries where used as part of routine practice
12 Recruiting Phase II Combination Steroid and Anti-Vegf for Persistent DME
Condition: Diabetic Macular Edema
Interventions: Drug: intravitreal ranibizumab 0.3 mg;   Drug: dexamethasone intravitreal implant;   Procedure: Sham injection
Outcome Measures: Mean change in visual acuity letter score;   At 24 weeks after randomization, percent of eyes with at least 10 and at least 15 letter gain (increase) or loss (decrease) in E-ETDRS letter score visual acuity.;   Visual acuity area under the curve (AUC) between randomization and 24 weeks;   Mean change in OCT CSF thickness, adjusted for thickness at time of randomization;   Percent of eyes with ≥1 and ≥2 logOCT step gain or loss in CSF thickness;   Percent of eyes with OCT CSF thickness < the gender-specific spectral domain OCT equivalent of 250 microns on Zeiss Stratus;   OCT CSF thickness area under the curve between randomization and 24 weeks;   Percent of eyes with worsening or improvement of diabetic retinopathy on clinical exam
13 Recruiting Vascular Endothelial Growth Factor (Vegf) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma
Condition: Metastatic Renal Cell Carcinoma
Intervention: Other: 89Zr-bevacizumab PET scan
Outcome Measures: Change in 89Zr-bevacizumab uptake in tumor lesions between the baseline scan and the scan during treatment;   Progressive disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria, after 3 months of treatment
14 Unknown  Role of Vascular Endothelial Growth Factor (Vegf) in Acute Lung Injury/Adult Respiratory Distress Syndrome (ARDS)
Condition: Respiratory Distress Syndrome, Adult
Intervention:
Outcome Measure:
15 Unknown  Effect of Bevacizumab and Vegf on Platelet Clustering in Patients Who Are Receiving Bevacizumab for Cancer
Conditions: Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: bevacizumab;   Other: coagulation study;   Other: laboratory biomarker analysis;   Other: platelet aggregation test
Outcome Measures: Influence of bevacizumab on platelet aggregation;   Influence of Vegf on platelet aggregation;   Influence of Vegf or bevacizumab on cyclooxygenesis;   Correlation between medication sequence and platelet aggregation
16 Recruiting Vegf Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-Vegf Agents
Condition: Macular Degeneration
Intervention:
Outcome Measure:
17 Recruiting Treatment for CI-DME in Eyes With Very Good VA Study
Condition: Diabetic Macular Edema
Interventions: Procedure: Prompt Laser;   Drug: Prompt aflibercept;   Procedure: Deferred laser;   Drug: Deferred aflibercept
Outcome Measures: Percent of eyes that have lost at least 5 letters of visual acuity at 2 years compared with baseline mean visual acuity;   Percent of eyes with at least 5, 10 and 15 letter losses in visual acuity from baseline mean visual acuity;   Percent of eyes with at least 5 letter gain in visual acuity from baseline mean visual acuity;   Mean change in visual acuity, adjusted for baseline mean visual acuity;   Visual acuity area under the curve between baseline and annual visits;   Mean change in OCT CSF thickness, adjusted for baseline mean thickness;   Percent of eyes with at least a 1 and 2 log step increase or decrease on OCT CSF thickness;   Percent of eyes with OCT CSF thickness of <250 µm on Stratus OCT (or spectral domain equivalent) and at least a 10% OCT CSF thickness decrease;   Number of injections and/or focal/grid photocoagulation sessions performed;   Number of scheduled and unscheduled visits;   Percent of eyes with worsening diabetic retinopathy;   Of eyes with non-proliferative diabetic retinopathy or proliferative diabetic retinopathy (PDR) at randomization, percent with improvement in diabetic retinopathy;   Of eyes with PDR at randomization, proportion of eyes avoiding vitreous hemorrhage or panretinal photocoagulation (PRP) or vitrectomy for PDR;   Mean change in low-contrast visual acuity on Electronic Visual Acuity Tester;   Total cost of follow-up and treatment;   For eyes randomized to deferred anti-Vegf, the percentage of eyes needing anti-Vegf treatment.
18 Recruiting Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
Conditions: Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Biological: trebananib;   Biological: bevacizumab;   Drug: pazopanib hydrochloride;   Drug: sorafenib tosylate;   Drug: sunitinib malate;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Overall tumor response rate defined as the total number of efficacy-evaluable patients who achieve a complete or partial response by Response Evaluation Criteria in Solid Tumors version 1.1 criteria;   Progression free survival (PFS);   Tolerance of trebananib alone and in combination with anti-Vegf agent assessed using Common Terminology Criteria for Adverse Events version 4.0;   Toxicity of trebananib alone and in combination with anti-Vegf agent assessed using Common Terminology Criteria for Adverse Events version 4.0
19 Recruiting Characterization of Eyes With Diabetic Macular Edema That Show Different Treatment Response to Intravitreal Anti-Vegf (CHARTRES)
Condition: Diabetic Macular Edema
Intervention:
Outcome Measures: Central Retinal Thickness (Change from screening);   Presence (and location) of cysts in the retinal layers (change from screening);   Presence of OCT diffuse macular edema (without cyst formation) (change from screening);   Presence of neurosensorial retinal detachment. (change from screening);   Degree of integrity of the photoreceptors in the inner/outer segments layer in the 1 mm centered in the fovea (change from screening);   Presence and extension of capillary occlusion (change from screening);   Area of macular leakage (intraretinal fluid volume and retinal thickness) (change frmo screening);   Best Corrected Visual Acuity (BCVA) (Change from screening);   Central Retinal Thickness (change from screening);   Area of macular leakage (intraretinal fluid volume and retinal thickness) (change from screening);   Best Corrected Visual Acuity (change from screening)
20 Not yet recruiting Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept
Condition: Exudative Age-related Macular Degeneration
Intervention: Drug: Aflibercept
Outcome Measures: Mean change in Vegf plasma concentration (pg/mL);   Mean change in Visual Acuity as measured with the Snellen chart;   Central Retinal Thickness as measured by Optical coherence tomography expressed in microns;   Number of non-responders